INGN vs. COCH, CLGN, RBOT, SMTI, MLSS, LFWD, ZJYL, SCLX, PIII, and OBIO
Should you be buying Inogen stock or one of its competitors? The main competitors of Inogen include Envoy Medical (COCH), CollPlant Biotechnologies (CLGN), Vicarious Surgical (RBOT), Sanara MedTech (SMTI), Milestone Scientific (MLSS), ReWalk Robotics (LFWD), Jin Medical International (ZJYL), Scilex (SCLX), P3 Health Partners (PIII), and Orchestra BioMed (OBIO). These companies are all part of the "medical" sector.
Inogen (NASDAQ:INGN) and Envoy Medical (NASDAQ:COCH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.
Inogen has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500.
Inogen received 383 more outperform votes than Envoy Medical when rated by MarketBeat users. However, 100.00% of users gave Envoy Medical an outperform vote while only 70.57% of users gave Inogen an outperform vote.
Envoy Medical has a net margin of 0.00% compared to Inogen's net margin of -32.46%. Envoy Medical's return on equity of 0.00% beat Inogen's return on equity.
Envoy Medical has lower revenue, but higher earnings than Inogen.
In the previous week, Inogen had 2 more articles in the media than Envoy Medical. MarketBeat recorded 3 mentions for Inogen and 1 mentions for Envoy Medical. Inogen's average media sentiment score of 1.16 beat Envoy Medical's score of 0.00 indicating that Inogen is being referred to more favorably in the media.
89.9% of Inogen shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 1.0% of Inogen shares are owned by insiders. Comparatively, 0.7% of Envoy Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Inogen presently has a consensus target price of $7.50, suggesting a potential upside of 4.90%. Envoy Medical has a consensus target price of $6.00, suggesting a potential upside of 37.93%. Given Envoy Medical's stronger consensus rating and higher probable upside, analysts clearly believe Envoy Medical is more favorable than Inogen.
Summary
Envoy Medical beats Inogen on 9 of the 16 factors compared between the two stocks.
Get Inogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
